Climb Bio to present preliminary Phase 2 PrisMN trial data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026
Bitget2026/10/02 13:30- Climb Bio flagged new clinical updates for CLYM116 and budoprutug ahead of ASN Kidney Week 2026 in Denver on Oct. 21-25.
- Preliminary Phase 2 results from the PrisMN study of budoprutug in primary membranous nephropathy will be presented on Oct. 24.
- The readout is positioned as an early look at safety and efficacy, marking a key milestone for the CD19 antibody program.
- Phase 1 data for CLYM116 in healthy volunteers will be presented on Oct. 22-23, supporting development in IgA nephropathy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000
PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.
Altcoin Rises 138% in One Month and Enters Top 20, What’s Behind the Rally? Here Are the Details
OpenAI's annualized revenue aims for $70 billions, with enterprise business as a driving force
According to sources familiar with the matter, OpenAI is expected to reach or exceed an annualized revenue of 7 billion dollars by the end of this year, mainly driven by the growth of its enterprise business.
October 9 Crypto News and Market Trends | BTC/ETH/SOL Resistance & Support
Crypto prices
More
